RGS vs SKIN

For growth investors, Regis Corporation (RGS) is the stronger pick with 3.

5% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Regis Corporation (RGS) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate The Beauty Health Company (SKIN) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regis Corporation (RGS) delivered a total return of -86.

9%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: RGS returned -90. 1% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regis Corporation (RGS) is the lower-risk stock at 0.

79β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 154% more volatile than RGS relative to the S&P 500. On balance sheet safety, Regis Corporation (RGS) carries a lower debt/equity ratio of 189% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regis Corporation (RGS) is pulling ahead at 3.

5% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to 13. 9% for Regis Corporation. Over a 3-year CAGR, SKIN leads at -6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regis Corporation (RGS) is the more profitable company, earning 58.

8% net margin versus -3. 2% for The Beauty Health Company — meaning it keeps 58. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGS leads at 9. 5% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Regis Corporation (RGS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

79)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RGS: -90. 1%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RGS (Consumer Cyclical) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RGS is a small-cap deep-value stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.